



Attorney Docket No. 09800080-0104

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Group Art Unit:
)	
David P. Andrew et al.)	Examiner:
)	
Application No. 10/614,599)	
)	
Filed: July 7, 2003)	
)	
For: WNT-REGULATED CYTOKINE-)	
LIKE POLYPEPTIDE AND NUCLEIC)	
ACIDS ENCODING SAME)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))**

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).


The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

Transmittal of Information Disclosure Statement
Page 2

Each item of information contained in this information disclosure statement was cited in parent application serial number 09/715,747. Copies of these references may be found in parent application serial number 09/715,747.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Dated: November 14, 2003

Respectfully submitted,

By: _____
David E. Crawford, Jr., Reg. No. 38,118
Customer No. 26263
314.259.5810



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/614,599	
				Filing Date	July 7, 2003	
				First Named Inventor	David P. Andrew	
				Group Art Unit	1647	
Sheet 1 of 3	Attorney Docket Number		09800080-0104			
U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	5,871,697	02/16/1999	Rothberg et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	2	WO 97/34013	09/18/1997	MAN Genome Sciences, Inc.		<input type="checkbox"/>
	3	WO 99/47669	09/23/1999	Schmitt et al.		<input type="checkbox"/>
	4	WO 01/00828	01/04/2001	Corixa Corp.		<input type="checkbox"/>
Examiner Signature			Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box ☒

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info unless it contains a valid OMB control no.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/614,599		
		Filing Date	July 7, 2003		
		First Named Inventor	David P. Andrew		
		Group Art Unit			
		Examiner Name	Regina M. Deberry		
Sheet	2	of	3	Attorney Docket No.	09800080-0104
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	5	ADAMS, M.D. et al., "EST 186826 HCC Cell Line (Metastasis to Liver in Mouse) II Homo Sapiens CDNA 5' End mRNA Sequence", Accession Number: AA315020, 1997, AND Adams M.D. et al., "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA", Nature, vol. 377, (1995), pp 3-174.			
	6	CAMBY, I., F. Lefranc, et al., "Differential expression of S100 Calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours", Neuropathology and Applied Neurobiology, 26 (2000), pp 76-90.			
	7	DALE, I., M. K. Fagerhol, et al., "Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen", Euro J Biochem 134 (1983), pp 1-6.			
	8	DE FERRARI, G. V. and N. C. Inestrosa, "Wnt signaling function in Alzheimer's disease", Brain Research Reviews 33 (2000), p 1-12.			
	9	DJUKANOVIC, D., U. Hofmann, et al., "Comparison of S100 protein and MIA protein as serum marker for malignant melanoma", Anticancer Research, 20 (2000), pp 2203-2208.			
	10	DONATO, R., "Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type", Biochimica et Biophysica Acta 1450 (1999), pp 191-231.			
	11	HUANG, X., A contig assembly program based on sensitive detection of fragment overlaps" Genomics 14 (1992), pp 18-25.			
	12	KERLAVAGE, A.R., Direct Submission. GenBank Accession Number AA315020, 1997, pp 1-2.			
	13	KLIGMAN, D. and D. C. Hilt, "The S100 protein family", Trends Biochemistry Science 13 (1988), pp 437-443.			
	14	KUHL, M., L. C. Sheldahl, et al., "The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape", Trends Genet 16 (2000), pp 279-283.			
	15	MARRA, M. et al., "The WashU-HMMI Mouse EST Project", Accession Number: W20659, (1996), Nucleotides, pp. 1-1074.			
	16	MARRA, M. et al., "The WashU-HHMI Mouse EST Project", Accession Number: W34209, (1997), Nucleotides, pp 166-377.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/614,599
				Filing Date	July 7, 2003
				First Named Inventor	David P. Andrew
				Group Art Unit	
Examiner Name	Regina M. Deberry				
Attorney Docket No.	09800080-0104				
Sheet	3	of	3		
OTHER ITEMS – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	17	MARRA, M. et al., "The WashU-HHMI Mouse EST Project", Accession Number: AA638675, (1997), Nucleotides, pp. 175-386.			
	18	MARRA, M. et al., "The WashU-HHMI Mouse EST Project", Accession Number: 726094, (1998), Nucleotides, pp. 1-483.			
	19	NACKEN, W., C. Sopalla, et al., "Biochemical characterization of the murine S100A9 (MRP14) protein suggests that it is functionally equivalent to its human counterpart despite its low degree of sequence homology", Eur J Biochem 267 (2000), pp 560-565.			
	20	PATAPOUTIAN, A. and L. F. Reichardt, "Roles of Wnt proteins in neural development and maintenance" Curr Opin Neurobiol 10 (2000), pp 392-399.			
	21	PEIFER, M. and P. Polakis, "Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus", Science 287 (2000), pp 1606-1609.			
	22	PIETAS, et al., "Human cDNA of a new member of the s100 protein family which is downregulated in lung carcinoma cells" Direct Submission. GenBank Accession Number: AY007220, 2000, pp 1-2.			
	23	SASTRY, M., R. R. Ketchem, et al., "The three-dimensional structure of Ca(2+)-bound calcyclin: implications for Ca(2+)-signal transduction by S100 proteins", Structure 6 (1998), pp 223-231.			
	24	SHENG, J. G., R. E. Mrak, et al., "Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice", J Neurochem 74 (2000), pp 295-301.			
	25	SHIMKETS, R. A., D. G. Lowe, et al., "Gene expression analysis by transcript profiling coupled to a gene database query", Nature Biotechnology 17 (1999), pp 798-803.			
	26	SMALLEY, M. J. and T. C. Dale, "Wnt signaling in mammalian development and cancer" Cancer Metastasis Rev 18 (1999), pp 1-2) (Abstract only).			
	27	XU, K. and C. L. Ceczy, "IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8", The Journal of Immunology (2000), pp 4916-4923.			
Examiner Signature				Date Considered	